Carna Biosciences, Inc.
Karna Biotechnology, Inc. Second Quarter (Interim) Financial Summary〔Japanese GAAP〕(Consolidated)【2026-08-06】
Announces the results for the second quarter of the fiscal year ending December 2026. Net sales were 401 million yen (YoY +59.8%), operating loss was 954 million yen, and net loss attributable to owners of the parent for the interim period was 1,039 million yen. Full-year guidance: net sales of 720 million yen and net loss for the period of 20.9 billion yen, with -108.95 yen per share. Although the drug discovery business remains in deficit, the drug discovery support business is expanding in revenue and profitability. Capital policy includes fund-raising through exercise of stock acquisition rights and bond issuance. There is material uncertainty related to the continuation of the company as a going concern.
Key Figures
- Net sales: 401,154 千円
- Operating loss: -954,112 千円
- Net loss attributable to owners of the parent for the interim period: -1,039,782 千円
AI要約
Overview of results
While the drug discovery business continues progression across multiple pipelines and collaborations, the drug discovery support business is expanding revenue regionally, and the interim-period consolidated net sales reached 401 million yen, significantly higher year over year. Operating loss was 954 million yen, ordinary loss 1,005 million yen, and net loss attributable to owners of the parent for the interim period was 1,039 million yen. Full-year projections are net sales of 720 million yen and net loss of approximately 20.9 billion yen. Capital policies have been implemented to strengthen the financial base. There is material uncertainty regarding the assumption of a going concern.
Outlook and capital policy
For the full year ending December 2026, the full-year forecast is net sales of 720 million yen, with no reduction in both ordinary income and net loss attributable to owners of the parent, and net loss for the period is expected to be approximately 20.9 billion yen. On the financial front, funds are being secured through the issuance of two unsecured bonds, exercise of convertible bonds and stock acquisition rights, and other capital strengthening measures. As of the interim end, the company remains in a negative equity position, and future licensing revenue and licensing agreements may improve the financial position depending on the status of such contracts.
Karna Biotechnology, Inc.
Company overview · Stock price · Financial data · All IR
